Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 154

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 154
---
 seek companies with fundamentally sound business models that will recover well. • Multiple avenues for long -term growth: We intend to acquire a company that exhibits long -termgrowth prospects, with the potential to grow both organically and inorganically through acquisitions, and demonstrates the ability to drive growth through the enablement or scaling of technology. • Sustainable financial profile: We intend to target companies that generate stable free cash -flowand are not reliant on financial leverage to generate returns. • Compelling value proposition: We intend to acquire a fundamentally sound business that is underperforming its potential but presents a compelling value proposition relative to its peers that may result in an attractive risk -adjustedreturn for our shareholders. • Potential for add -on acquisitions: We will actively consider target companies that would serve as a strong platform for post -closingadd -onacquisitions. Given our extensive industry networks and collective experience, we believe we will have unique access to a large number of private assets operating in the pharmaceutical sector. Such add -onacquisitions can expedite growth for the target and help to amplify returns for our shareholders. • Benefit from our unique capabilities: We seek to acquire a business that will benefit from and capitalize on our team’s unique operating expertise, extensive industry network and financing experience. 97 • Qualified management team: We seek to acquire a business that allows our team to partner with proven and established management teams or business owners to achieve long -termstrategic and operational excellence. • Benefit from being a public company: We intend to acquire a company at the point in its lifecycle at which going public, with the support of our highly experienced management team and access to our robust industry networks, is a natural next step and that will benefit from access to a public currency to accelerate growth. • Products and Services provided:Based on our team’s unique experience and skillset, we intend to source and evaluate companies focused on the pharmaceutical sector. This non -exclusivelist of criteria is not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on some or all of these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our shareholder communications related to our initial business combination, which, as discussed in this prospectus, would be in the form of